Latest News - FDA Approval/Clearance

Tuesday, April 18, 2017 | FDA Approval/Clearance, Pain & Headache

FDA Releases Non-Invasive VNS Therapy for Pain Associated with Episodic Cluster Headache

The FDA has released the use of gammaCore, a non-invasive vagus nerve stimulator for the acute treatment of pain associated with episodic cluster headache in adult patients. gammaCore transmits a mild…

Read the full story

Wednesday, April 12, 2017 | FDA Approval/Clearance, Movement Disorders, Product Launches and Updates

First Treatment for Tardive Dyskinesia Approved in US

The FDA approved the selective VMAT2 inhibitor Ingrezza (valbenazine, Neurocrine Biosciences), making it the first treatment approved in the US to treat adults with tardive dyskinesia. The efficacy of…

Read the full story

Tuesday, April 04, 2017 | FDA Approval/Clearance, Movement Disorders, Neuromuscular & Immune Disorders, Phase 3/4 Trials

New Therapy for Chorea Associated with Huntington’s Disease Wins FDA Approval

The FDA approved Austedo (deutetrabenazine, Teva Pharmaceuticals) tablets for the treatment of chorea associated with Huntington’s disease (HD), making it just the second product approved for th…

Read the full story

Thursday, March 30, 2017 | FDA Approval/Clearance, Pain & Headache

FDA Approves Expanded Indication For Qudexy XR Extended Release Capsules

The FDA has approved two supplemental indications for Qudexy XR (topiramate, Upsher-Smith) Extended Release Capsules for use as prophylaxis of migraine headache in adults and adolescents 12 years of a…

Read the full story

Tuesday, March 28, 2017 | Clinical Trials, FDA Approval/Clearance, Neuromuscular & Immune Disorders, Phase 3/4 Trials, Research and Publications, Genentech, Roche

Ocrevus Receives FDA Greenlight for Relapsing, Primary Progressive Forms of Multiple Sclerosis

The FDA has approved Ocrevus (ocrelizumab, Roche/Genentech) for the treatment of both relapsing and primary progressive forms of multiple sclerosis. Ocrelizumab is a humanized antibody that …

Read the full story

Wednesday, March 22, 2017 | FDA Approval/Clearance, Movement Disorders

Novel Adjunct Agent Approved for Parkinson’s "Off" Periods

The FDA approved Xadago (safinamide, Newron Pharmaceuticals) tablets as an add-on treatment for patients with Parkinson’s disease who are currently taking levodopa/carbidopa and experiencing &ld…

Read the full story

Friday, February 10, 2017 | FDA Approval/Clearance, Neuromuscular & Immune Disorders

New Corticosteroid Approved for Duchenne Muscular Dystrophy

The FDA approved Emflaza (deflazacort) tablets and oral suspension to treat patients age five years and older with Duchenne muscular dystrophy (DMD). Emflaza is the first FDA approved corticosteroid t…

Read the full story

Wednesday, January 25, 2017 | Dementia & Cognitive Disorders, FDA Approval/Clearance, Product Launches and Updates

Memory Impairment Screening Tool Gains FDA Clearance

The FDA has granted 510(k) clearance to CANTAB Mobile (Cambridge Cognition), a sensitive screening tool for the detection clinically-relevant memory impairment in older adults at the point of care. CA…

Read the full story

Wednesday, December 21, 2016 | FDA Approval/Clearance, Neuromuscular & Immune Disorders, Genentech, Roche

FDA Extends Review of MS Agent Ocrevus to March 2017

The FDA has extended the Prescription Drug User Fee Act (PDUFA) date for its review of the Biologics License Application of Genentech’s investigational agent for the treatment of multiple sclero…

Read the full story

Tuesday, November 15, 2016 | FDA Approval/Clearance, Pain & Headache

New MRI Labeling Approved for St. Jude Medical’s SCS System

The FDA has approved new labeling for full-body magnetic resonance imaging (MRI) for St. Jude Medical’s Proclaim Elite Spinal Cord Stimulation (SCS) System. The new labeling ensures patients in …

Read the full story

Tuesday, November 01, 2016 | FDA Approval/Clearance, Product Launches and Updates

Portable Brain Monitoring Information System Gains FDA Clearance

A new portable ultrasound device designed for rapid triaging and monitoring of patients with brain disorders has been cleared by the FDA. The Lucid System uses Trans Cranial Doppler to non-invasively …

Read the full story

Monday, October 31, 2016 | FDA Approval/Clearance, Stroke & Cerebrovascular

PFO Occluder Approved to Reduce Risk of Recurrent Stroke

The FDA recently approved St. Jude Medical’s Amplatzer PFO Occluder to help reduce the risk of recurrent ischemic strokes in patients diagnosed with a patent foramen ovale (PFO). The Amplatzer P…

Read the full story

Friday, October 07, 2016 | FDA Approval/Clearance, Movement Disorders

New DBS System for Parkinson’s Disease, Essential Tremor Approved

The deep brain stimulation market will soon be expanding, as the FDA has approved St. Jude Medical’s Infinity system for the treatment Parkinson’s disease and essential tremor. Also approv…

Read the full story

Wednesday, October 05, 2016 | FDA Approval/Clearance, Pain & Headache

FDA Greenlights Spinal Cord Stimulation Therapy for Patients with Chronic Pain

The FDA has approved BurstDR stimulation, a physician-designed form of spinal cord stimulation (SCS) for patients with chronic pain. According to manufacturer St. Jude Medical, BurstDR helps phys…

Read the full story

Wednesday, September 28, 2016 | FDA Approval/Clearance, Visual & Sensory Disturbances

FDA Clears Handheld TBI Assessment Device

The FDA has cleared BrainScope’s newest device for the assessment of traumatic brain injury (TBI), the Ahead 300. Developed in partnership with the US Department of Defense, the Ahead 300 provid…

Read the full story
Load More